The Embryonic Stem Cell/Transqenic Mice (ES TGM) Shared Resource was reorganized in 2003, under the direction of Dr. Hong Wu (STT and GU) and the co-direction of Drs. Xin Liu and Meisheng Jiang. UCLA has provided new space for the ES cell facility and for the injection facility. The ES/TGM Shared Resource produces targeted genetic alterations in embryonic stem (ES) cells, knock-in mice, knock-out mice and transgenic mice for its clients. The Shared Resource also provides re-derivation services. Drs. Wu, Liu and Jiang provide consultation in vector design, experimental design, analysis of recombinant ES cells and analysis of chimeric offspring. The shared resource is designed to be as "turn key" for the investigator as possible. The ES service provides a series of alternative vectors for knock-in and knock-out constructs, ES cell lines, irradiated feeder cells, tested sera, mycoplasma testing, electroporation services and cloning of ES targeted cells. Investigators prepare the targeting vector, drop it off and identify appropriate clones by Southern blotting and/or PCR. Appropriate clones are delivered by the ES facility to the injection facility for blastocyst injection and investigators characterize progeny for germline transmission by genetic analysis of tail clips provided by the Shared Resource. The Transgenic facility also prepares transgenic mice with plasmid, BAG, and lentiviral vectors. Inbred strains are available for appropriate back crossing. The directors and the technical staff are experienced and experts in their fields. Turn-around times for ES cell delivery and for transgenic mouse delivery are close to the minimum times possible for the biological processes. Homologous recombination to produce targeted ES cell clones has been 100% successful and generation of genetically modified mouse strains is greater than 95%. The Shared Resource also works to establish new technologies and to integrate state-of-the-art advances (e.g., use of BAG and lentiviral vectors) into procedures available to clients. During the current CCSG cycle the ES/TGM Shared Resource has created 74 targeted strains and 85 transgenic strains;24 Cancer Center members representing seven Program Areas have utilized the services of the ES TGM Shared Resource during the current CCSG cycle, to produce 65 percent of these mice. (Please also see Section 6,2.3 on Shared Resources in the History, Description, Essential Characteristics). 18 Cancer Center members representing 7 Cancer Center Program Areas utilized the services of the Embryonic Stem Cell/Transgenic Mouse Shared Resource during the reporting period. This is a continuing shared resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016042-38
Application #
8392136
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$188,613
Indirect Cost
$66,159
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications